BlackRock spearheaded a $257 million Series D financing for Cellares alongside Eclipse, raising the cell therapy IDMO’s total funding to $612 million. The deal attracted new strategic investors such as T. Rowe Price, Baillie Gifford and Duquesne Family Office. BlackRock’s commitment underscores its growing interest in venture-stage life-science platforms and automation technologies aimed at scaling therapeutic manufacturing globally.

In a bid to bolster board expertise, BlackRock elected Gregg R. Lemkau—Co-CEO of BDT & MSD Partners—as an independent director, bringing the board to 19 members, 16 of whom are independent. Since 2020, six new independent directors have been added, reflecting a deliberate strategy to diversify backgrounds in merchant banking, technology and family-office advisory. Lemkau’s track record includes advising on over $1 trillion in transactions during a 28-year tenure at Goldman Sachs and chairing Dartmouth College’s Board of Trustees.

Prediction markets now peg BlackRock’s Global Fixed Income CIO, Rick Rieder, at a 51% probability of succeeding Jerome Powell as Federal Reserve Chair. Rieder manages a $2.5 trillion bond portfolio and led BlackRock’s role in the Fed’s 2020 corporate-bond purchase program. His public view is that benchmark rates near 3% would better serve housing and small-business recoveries, below current levels but above the administration’s preferred rate target.

BlackRock grew retail assets under management from $1 trillion to $1.25 trillion year-over-year, driven by lower-fee index products. However, institutional inflows into passive funds have eroded performance-fee contributions. Management responded with a 10% dividend hike and a $7 billion share repurchase authorization, reflecting confidence in cash-flow generation but suggesting investors maintain a neutral stance on near-term margin compression.